Shots:
- Sanofi has reported the P-III (Baby-COMET) trial results assessing Nexviazyme (avalglucosidase alfa; 40mg/kg, Q2W, IV) in 17 treatment-naïve pediatric pts (≤12mos.) with IOPD
- Trial met its 1EP, with more treatment-naïve pts (≤6mos.) alive & free of invasive ventilation at 52wks., and achieved all 2EPs, including higher survival without invasive ventilation in pts at 12 & 18mos. of age, plus numerical improvements in other disease progression measures at Wk. 52
- Nexviazyme is an ERT designed for enhanced M6P receptor binding, delivering ~15-fold higher M6P content than Myozyme/Lumizyme to improve cellular uptake and glycogen clearance
Ref: Globenewswire | Image: Sanofi | Press Release
Related News: Sanofi Reports the EC Approval for Cenrifki (Tolebrutinib) to Treat SPMS without Relapses
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
